What Novo Holdings A/S reported holding on Form 13F for the quarter ended Jun 30, 2026.
CIK 1388325 · Filed Aug 14, 2026
Values are as the managers reported them, in dollars.Open the Form 13F on SEC EDGAR
| 94.9K |
| ±0% |
| $188.9M |
| 11% |
COAGHemab Therapeutics Holdings, Inc. | 4.2M | New | $153.6M | 8.9% |
BNBROOKFIELD Corp | 3.5M | ±0% | $149.5M | 8.7% |
MPLTMapLight Therapeutics, Inc. | 3.7M | ±0% | $132.1M | 7.7% |
MIRMMirum Pharmaceuticals, Inc. | 1.1M | −15.1% | $131.7M | 7.6% |
AVLNAvalyn Pharma Inc. | 3.9M | New | $127.8M | 7.4% |
CRMSalesforce, Inc. | 393.2K | ±0% | $61.6M | 3.6% |
AVBPArriVent BioPharma, Inc. | 1.5M | −22.8% | $52.1M | 3% |
ELVNEnliven Therapeutics, Inc. | 1M | −21.9% | $50.8M | 2.9% |
CRNXCrinetics Pharmaceuticals, Inc. | 1.3M | −14.8% | $49.4M | 2.9% |
PHVSPharvaris N.V. | 1.4M | −20.0% | $48.4M | 2.8% |
FNDFloor & Decor Holdings, Inc. | 797K | New | $47.3M | 2.7% |
PCVXVaxcyte, Inc. | 800K | −7.0% | $46.5M | 2.7% |
FDMT4D Molecular Therapeutics, Inc. | 3.2M | −11.0% | $43.2M | 2.5% |
VRDNViridian Therapeutics, Inc. | 2.1M | +6.8% | $39.2M | 2.3% |
CLDXCelldex Therapeutics, Inc. | 1M | −14.6% | $38.1M | 2.2% |
ALMSAlumis Inc. | 1.1M | New | $31M | 1.8% |
XENEXenon Pharmaceuticals Inc. | 485.4K | ±0% | $29.3M | 1.7% |
BABAAlibaba Group Holding Ltd | 257.3K | ±0% | $24.7M | 1.4% |
DYNDyne Therapeutics, Inc. | 960.4K | New | $21.3M | 1.2% |
BBOTBridgeBio Oncology Therapeutics, Inc. | 2.3M | +2.9% | $17.1M | 1% |
INSMINSMED Inc | 120.7K | New | $12.9M | 0.7% |
MQMarqeta, Inc. | 441.6K | ±0% | $7.2M | 0.4% |
LNZALanzaTech Global, Inc. | 158.1K | ±0% | $1.1M | 0.1% |
